Grace Therapeutics, Inc.
Late-stage biopharma developing drugs for rare and orphan neurological conditions.
GRCE | US
Overview
Corporate Details
- ISIN(s):
- US00439U1043 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 103 CARNEGIE CENTER, 8540 PRINCETON
- Website:
- https://www.gracetx.com/
- Sector:
- Manufacturing
Description
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company that develops drug candidates for rare and orphan diseases, with a primary focus on neurological conditions. The company's lead clinical asset is GTx-104, a novel intravenous (IV) formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH), a life-threatening brain injury. GTx-104 is designed to overcome the clinical challenges of the current oral standard of care, such as administration difficulties in critically ill patients and high pharmacokinetic variability. The product is currently in a pivotal Phase 3 clinical trial. Grace Therapeutics utilizes proprietary drug delivery technologies to improve the performance of marketed drugs, and its lead assets have received Orphan Drug Designation from the U.S. Food and Drug Administration.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Grace Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Grace Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Grace Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
